InsiderSignal.AI

InsiderSignal.ai

KYMR - Kymera Therapeutics, Inc.

Insider Sale by Esposito Pamela (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Esposito Pamela, serving as Dir at Kymera Therapeutics, Inc. (KYMR), sold 2,500 shares at $87.31 per share, for a total transaction value of $218,270.00.

This sale represents a 100.00% decrease in Esposito Pamela's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 20, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, meaning the disclosure happened on the same day as the trade.

Kymera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Esposito Pamela

Dir

Pamela Esposito, Ph.D. is an independent Class I director at Kymera Therapeutics, Inc. (KYMR), serving since September 2020.[[1]](https://fintool.com/app/research/companies/KYMR/people/pamela-esposito)[[6]](https://www.kymeratx.com/about-us/leadership/) She recently exercised options for 5,500 shares and sold them on January 20, 2026, under a Rule 10b5-1 trading plan dated September 17, 2025, leaving her direct common stock holdings at zero while retaining vested options.[[4]](https://www.investing.com/news/insider-trading-news/kymera-therapeutics-director-esposito-sells-373k-in-shares-93CH-4456638)[[5]](https://www.stocktitan.net/sec-filings/KYMR/form-4-kymera-therapeutics-inc-insider-trading-activity-e3dfc73df1a3.html) Esposito brings over 25 years of experience in biopharma strategy, business development, and corporate development.[[2]](https://accenttx.com/team/pamela-esposito-phd/)[[3]](https://sapiencetherapeutics.com/pamela-esposito-ph-d/) She was a founding Chief Business Officer at Replimune Group, Inc. from 2015 to March 2024 (now consulting), where she raised approximately $1 billion in capital; previously CBO at Ra Pharmaceuticals (2013–2015), aiding its transition to clinical-stage; VP Business Development at BioVex (leading its Amgen acquisition); and roles at Angiochem, Bioduro, and Vion Pharmaceuticals.[[1]](https://fintool.com/app/research/companies/KYMR/people/pamela-esposito)[[2]](https://accenttx.com/team/pamela-esposito-phd/)[[3]](https://sapiencetherapeutics.com/pamela-esposito-ph-d/) She serves on boards of Sapience Therapeutics and Accent Therapeutics, plus private companies, and on KYMR's Audit and Nominating & Corporate Governance Committees.[[1]](https://fintool.com/app/research/companies/KYMR/people/pamela-esposito)[[2]](https://accenttx.com/team/pamela-esposito-phd/)[[3]](https://sapiencetherapeutics.com/pamela-esposito-ph-d/) Esposito holds a Ph.D. in Pharmacology from Tufts University School of Medicine and a B.A. in Biochemistry/Molecular Biology from Dartmouth College.[[1]](https://fintool.com/app/research/companies/KYMR/people/pamela-esposito)[[3]](https://sapiencetherapeutics.com/pamela-esposito-ph-d/)

View full insider profile →

Trade Price

$87.31

Quantity

2,500

Total Value

$218,270.00

Shares Owned

0

Trade Date

Friday, February 20, 2026

1 days ago

SEC Filing Date

Friday, February 20, 2026

HEALTHCAREBIOTECHNOLOGY

About Kymera Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KYMR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4154755

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime